Pre-transplant downstaging strategies for hepatocellular carcinoma with portal vein tumor thrombus: Current therapies and future challenges [0.03%]
肝癌门静脉癌栓的移植前降级治疗策略：当前疗法与未来挑战
Zong-Yang Li,Cheng Xie,Hong-Qiao Cai
Zong-Yang Li
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide, with approximately 35%-50% of patients presenting concurrent portal vein tumor thrombus (PVTT). Untreated HCC patients with PVTT have a ...
Intra-rater reliability of the 6-min walk test in people with liver cirrhosis [0.03%]
肝硬化患者6分钟步行试验的同评价者可靠性
Fabiana Coelho Couto Rocha Corrêa,Isabella Scarlatelli Telles Pires Nader,Maria Rita Silva Riolino et al.
Fabiana Coelho Couto Rocha Corrêa et al.
Background: Liver cirrhosis often leads to significant impairments in functional capacity, which are associated with disease severity and prognosis. Simple, reliable, and low-cost tests are essential to monitor these pati...
Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease [0.03%]
角蛋白18片段与脂肪变性相关纤维化评估评分和脂质之间的关系——一项针对脂肪肝病患者的队列研究
Tatsuki Ichikawa,Satoshi Miuma,Mio Yamashima et al.
Tatsuki Ichikawa et al.
Background: Serum cytokeratin 18 fragment (CK18F) has been developed as a new non-invasive test (NIT) for risk assessment of steatotic liver disease (SLD); however, there are few reports on its relationship with existing ...
Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Machine learning for non-invasive diagnosis and risk stratification [0.03%]
人工智能在代谢功能障碍相关脂肪性肝病中的应用：机器学习在非侵入性诊断和风险分层中的应用
Mona Abd-Elmonem Hegazy
Mona Abd-Elmonem Hegazy
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, represents a growing global health burden, contributing significantly to liver-related morbidity and mortality. Early det...
Meng-Jia Li,Chen-Lin Wen,Hai-Tao Cheng et al.
Meng-Jia Li et al.
PANoptosis is an inflammatory programmed cell death pathway possessing critical characteristics of apoptosis, pyroptosis, and necroptosis. It is regulated by PANoptosome complexes, involves interaction between these three key programmed cel...
Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis [0.03%]
短链脂肪酸在代谢功能异常相关性肝脂肪变性疾病和代谢功能异常相关性非酒精性steatohepatitis中的作用
Chun-Ye Zhang,Shuai Liu,Yu-Xiang Sui et al.
Chun-Ye Zhang et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, affecting more than 30% of adults and 7%-14% of youths globally. MASLD and its advanced form of metabolic dysfunction-associated stea...
Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes [0.03%]
重新定义脂肪肝代谢功能障碍相关性脂肪型肝病的临床意义：新的命名法对糖尿病患者的含义
Tulio L Correa,Nikki Duong
Tulio L Correa
The evolving nomenclature from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) aims to better encompass the metabolic context of the disease. This change has significant implicat...
Marco Fiore,Gianluigi Cosenza,Francesco Coppolino et al.
Marco Fiore et al.
Hypertransaminasemia - acute elevation of alanine aminotransferase and aspartate aminotransferase - is prevalent in non-cirrhotic adults admitted to the intensive care unit (ICU) and often signals extra-hepatic pathophysiology rather than i...
Beyond bones: Revisiting the role of vitamin D in chronic liver disease [0.03%]
超越骨骼：重新审视维生素D在慢性肝病中的作用
Rodrigo Guerrero-Guerrero,Osvely Mendez-Guerrero,Anaisa Carranza-Carrasco et al.
Rodrigo Guerrero-Guerrero et al.
Beyond its traditional role in calcium and bone metabolism, vitamin D has emerged as a critical regulator of liver health. Its active form, calcitriol [1α,25(OH)2D], signals through the vitamin D receptor (VDR), which is expressed in hepat...
Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease [0.03%]
代谢功能紊乱相关性肝脂肪变性疾病患者血清标志物评估肝纤维化的研究进展
Yan-Hua Zhao,Shu-Sheng Leng,Yan Wang et al.
Yan-Hua Zhao et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) requires accurate liver fibrosis assessment for management. While liver biopsy remains the gold standard, its invasiveness drives demand for non-invasive biomarkers. This revi...